重组人脑利钠肽治疗心内科重症监护室心力衰竭疗效观察

Efficacy of Recombinant Human Brain Natriuretic Peptide in the Treatment of Heart Failure in the Intensive Care Unit of Cardiology

目的探讨重组人脑利钠肽治疗心内科重症监护室心力衰竭的临床疗效。方法选取医院心内科重症监护室2021年2月至2023年2月收治的心力衰竭患者55例,采用双盲分组法分为对照组(27例)和治疗组(28例)。对照组患者给予常规治疗,治疗组患者在对照组基础上加用重组人脑利钠肽,对比两组患者的临床疗效。结果治疗组患者治疗后的心功能指标、B型脑利钠肽(BNP)、心率、N末端脑钠肽前体(NT-proBNP)均显著优于对照组(P<0.05);治疗组的治疗优良率为92.86%,显著高于对照组的70.37%(P<0.05);治疗组与对照组患者的不良反应发生率无显著差异(11.11%比17.86%,P>0.05)。结论重组人脑利钠肽治疗心内科重症监护室心力衰竭的临床疗效较好,可改善患者的心功能和血清指标,缓解其临床症状,且安全性良好。

Objective To investigate the clinical efficacy of recombinant human brain natriuretic peptide in the treatment of heart failure in the intensive care unit of cardiology.Methods A total of 55 patients with heart failure admitted to the intensive care unit of the cardiology department of the hospital from February 2021 to February 2023 were selected and divided into the control group(27 cases)and the treatment group(28 cases)using a double-blind grouping method.The control group received conventional treatment,while the treatment group received recombinant human brain natriuretic peptide in addition to the control group.The clinical efficacy of the two groups was compared.Results The cardiac function indicators,B-type brain natriuretic peptide(BNP),heart rate,and N-terminal proBNP in the treatment group were significantly better than those in the control group after treatment(P<0.05).The excellent and good treatment rate in the treatment group was 92.86%,which was significantly higher than 70.37%in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the treatment group and the control group(11.11%vs.17.86%,P>0.05).Conclusion Recombinant human brain natriuretic peptide therapy has good clinical efficacy in treating heart failure in the intensive care unit of cardiology,improving patients′cardiac function and serum indicators,alleviating their clinical symptoms,and has good safety.